Europe Dermatological Drugs Market Outlook, 2031

2026

Europe Dermatological Drugs Market Outlook, 2031

The Europe Dermatological Drugs Market is segmented into By Indication (Acne, Psoriasis, Atopic Dermatitis, Rosacea, Alopecia, Skin Cancer, Others), By Drug Class / Molecule Type (Corticosteroids, Biologics, Retinoids, Anti-infectives, Calcineurin Inhibitors, Others), By Route of Administration (Topical, Oral, Injectable / Parenteral), By Drug Type (Prescription-based Drugs, Over-the-Counter (OTC) Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies).

Bonafide Research
04-07-2026
Pages : 104
Figures : 9
Tables : 40
Region : Europe
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

The Europe Dermatological Drugs market is anticipated to add USD 3.98 billion during 2026–2031, driven by increasing skin disorder cases and innovative therapies.

Historical Period2020-2024
Base Year2025
Forecast Period2026-2031
Largest Market Germany
Fastest Market Spain
Market Difference(2026-31) USD 3.98 Billion
Format

Featured Companies

1. Johnson & Johnson,
2. Pfizer Inc.
3. Novartis International AG
4. Sanofi S.A.
5. AbbVie Inc.
6. Bausch Health Companies Inc.
More...

Highend Report

Highend report of this product is available

View

New Report Guarantee

If you purchase this report now and we update it in next 100 days, get it free!

Dermatological Drugs Market Analysis

The European dermatological drugs market represents a sophisticated and rapidly evolving therapeutic landscape, deeply integrated with the region's advanced healthcare infrastructure and rigorous regulatory framework. Over the past five years, this market has undergone a fundamental transformation, pivoting from conventional topical therapies toward precision biologic interventions and targeted oral small molecules, driven by the European Medicines Agency's progressive approval pathways. Over 6 million Germans suffer from eczema, with a high concentration of acute flare-ups occurring during dry winter conditions. Affects approximately 2.5 million people across the country, requiring long-term, continuous prescription maintenance. Moreover, nationwide population surveys show that over 25% of the German working population requires formal treatment for a dermatological condition at least once a year. In February 2026, the National Institute for Health and Care Excellence (NICE) officially recommended ruxolitinib cream (Opzelura) as the first licensed treatment to effectively restore skin pigment for vitiligo patients aged 12 and over on the NHS. Clinical trials validated that patients using the JAK-inhibitor cream were four to six times more likely to see visible repigmentation compared to a placebo. Italy, Spain, and Russia are expected to be among the fastest-growing markets in the European dermatological drugs market during the 2026–2031 forecast period. Italy currently has a market size of USD 750.72 million, Spain is projected to reach USD 935.53 million by 2031, and Russia is forecast to register a CAGR of 7.02% over the forecast period. The Committee for Medicinal Products for Human Use continues to shape the therapeutic landscape through positive opinions on novel agents, including ruxolitinib cream for moderate atopic dermatitis and nemolizumab for prurigo nodularis. According to the research report, "Europe Dermatological Drugs Market Outlook, 2031," published by Bonafide Research, the Europe Dermatological Drugs market is anticipated to add USD 3.98 Billion by 2026–31. France is projected to become the second-largest market in europe, with its market size expected to reach USD 1.95 billion by 203, whereas United Kingdom is anticipated to be the third-largest market, contributing an incremental growth of USD 537.44 million over the forecast period. Almirall has established itself as a formidable force in European medical dermatology, with its European dermatology business delivering net sales growth of 24.2% year-on-year, reaching €289.5 million in the first half of 2025. The company's biologic portfolio demonstrates exceptional momentum, with Ebglyss achieving net sales of €44.9 million more than quadrupling year-over-year across 14 European countries, while Ilumetri continues its steady growth trajectory with a 12.7% year-on-year increase to €113.3 million. Galderma has strengthened its European presence following the European Commission's approval of Nemluvio for moderate-to-severe atopic dermatitis and prurigo nodularis. The competitive landscape reflects substantial barriers to entry, including the European Medicines Agency's comprehensive regulatory requirements and the high cost of pan-European clinical development programs. Investment funding continues to flow toward novel drug discovery platforms, with pharmaceutical companies directing substantial capital toward JAK inhibitor development and digital health integration for dermatological consultations.

to Download this information in a PDF

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamics

Market Drivers• EMA Approval Acceleration: The European Medicines Agency's Committee for Medicinal Products for Human Use has accelerated the approval of transformative dermatological therapies. In February 2025, the CHMP recommended approval of nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis. In June 2026, the CHMP issued a positive opinion for ruxolitinib cream for moderate atopic dermatitis in adults. These regulatory actions expand treatment options across the region, driving market growth through increased patient access and earlier therapeutic intervention.
• Rising Disease Burden: The substantial prevalence of dermatological conditions across Europe creates sustained demand for advanced therapeutics. Approximately 4.4% of European adults and up to 18.6% of children and adolescents have atopic dermatitis. Psoriasis affects 1.92% of Western European and 1.83% of Central European populations. This substantial patient population, combined with growing awareness and earlier diagnosis, continues to drive market expansion across all therapeutic categories.

Market Challenges• HTA Reimbursement Complexity: The fragmented health technology assessment landscape across European nations creates significant market access challenges for pharmaceutical companies. Each country maintains independent reimbursement processes, with varying requirements for clinical and economic evidence. This complexity prolongs time-to-market and increases commercial uncertainty, particularly for innovative biologic and JAK inhibitor therapies that command premium pricing. The lack of harmonized reimbursement pathways across the European Union creates substantial barriers to market entry.
• Biosimilar Adoption Barriers: Despite the European Medicines Agency's approvals of biosimilar dermatological therapies, adoption across European markets remains inconsistent. National health systems vary considerably in their biosimilar substitution policies and physician prescribing incentives. The complexity of switching patients from reference biologics to biosimilars, combined with physician concerns regarding immunogenicity and interchangeability, continues to limit biosimilar uptake. These barriers perpetuate high treatment costs and constrain patient access to advanced therapies.

Market Trends• JAK Inhibitor Expansion: Janus kinase inhibitors represent a transformative drug class offering oral alternatives to injectable biologics across European dermatology. The CHMP's positive opinion for ruxolitinib cream for moderate atopic dermatitis in adults exemplifies this trend. Nemolizumab's approval for both atopic dermatitis and prurigo nodularis further demonstrates the expanding therapeutic footprint of targeted immunomodulators. These developments reflect the growing clinical acceptance of JAK inhibitors across multiple dermatological indications.
• Biologic Portfolio Growth: European dermatology companies are achieving substantial growth through biologic portfolio expansion. Almirall's Ebglyss achieved net sales of €44.9 million in the first half of 2025, representing more than quadruple year-over-year growth across 14 European countries. Ilumetri demonstrated 12.7% year-on-year growth to €113.3 million. These performance metrics underscore the increasing clinical adoption and commercial success of biologic therapies across European dermatology practices.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Kavita Mehra

Business Development Manager

Dermatological Drugs Segmentation

By Indication	Acne
	Psoriasis
	Atopic Dermatitis
	Rosacea
	Alopecia
	Skin Cancer
	Others
By Drug Class / Molecule Type	Corticosteroids
	Biologics
	Retinoids
	Anti-infectives
	Calcineurin Inhibitors
	Others
By Route of Administration	Topical
	Oral
	Injectable / Parenteral
By Drug Type	Prescription-based Drugs
	Over-the-Counter (OTC) Drugs
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Russia

Alopecia treatments are experiencing unprecedented growth driven by novel JAK inhibitor approvals, increasing disease awareness, and expanding therapeutic options across Europe. The alopecia treatment landscape has been revolutionized by the introduction of Janus kinase inhibitors targeting autoimmune-mediated hair loss pathways. In 2023, EU4 countries and the UK reported approximately 855 thousand diagnosed prevalent cases of alopecia areata. Germany alone recorded approximately 170,000 people diagnosed with alopecia areata in 2020. International data show a pooled prevalence of 2.1%, with substantial regional variations across Europe. Approximately 40% of patients develop symptoms before the age of 20 years. The presence of multiple approved therapies with different mechanisms creates a competitive landscape driving innovation. Increasing awareness about alopecia treatments has accelerated diagnosis rates and treatment-seeking behavior across European nations. The rising prevalence of autoimmune triggers such as stress, environmental pollution, and dietary changes continues to expand the addressable patient population. Biologics dominate the European dermatological drugs market through superior efficacy in treating chronic inflammatory conditions and expanding indications across multiple disease states. Biologics have fundamentally transformed dermatological care across Europe by offering targeted mechanisms that modulate specific immune pathways with unprecedented precision. Almirall's biologic portfolio demonstrates this dominance, with Ebglyss achieving €44.9 million in net sales during the first half of 2025 more than quadrupling year-over-year. Ilumetri continued its steady growth with a 12.7% year-on-year increase to €113.3 million. The European dermatology business delivered strong growth with net sales increasing by 24.2% year-on-year to €289.5 million. Biologics offer favorable safety profiles as confirmed by extensive clinical trial data across European populations. The joint EADV guidelines reaffirm the role of advanced biologic therapies in comprehensive dermatology management. Ongoing research continues to identify new biologic targets for dermatological conditions, expanding the therapeutic arsenal available to European clinicians. The availability of biosimilars is gradually expanding treatment access while maintaining rigorous efficacy standards across European healthcare systems. Oral dermatological drugs are rapidly gaining traction across Europe due to patient preference for non-invasive administration and the emergence of highly effective oral JAK inhibitors. The oral route of administration addresses a critical patient need for convenient, self-administered therapies that eliminate the discomfort and logistical challenges associated with injectable treatments. JAK inhibitors have demonstrated exceptional efficacy across multiple dermatological indications in European clinical trials. Oral therapies eliminate the need for healthcare facility visits for administration, significantly reducing treatment burden for patients. Patient adherence improves substantially with oral medications compared to injectable alternatives requiring clinical administration. Oral administration enables flexible dosing regimens that can be adjusted based on individual clinical response. The development of oral formulations for conditions traditionally treated with topical or injectable therapies is expanding the addressable patient population. The CHMP's positive opinion for ruxolitinib cream represents a significant advancement in oral and topical JAK inhibitor therapy. European dermatologists increasingly prescribe oral therapies as first-line interventions for moderate-to-severe inflammatory skin conditions. Prescription dermatological drugs are experiencing accelerated growth across Europe driven by innovative biologics, JAK inhibitors, and targeted therapies requiring medical supervision. Prescription-based dermatological drugs dominate the European market due to the complexity of chronic skin conditions necessitating physician-guided treatment selection and monitoring. Innovative biologics and JAK inhibitors require prescription status due to their potent mechanisms and potential side effect profiles. The complexity of chronic skin conditions necessitates physician-guided treatment selection and ongoing monitoring across European healthcare systems. Prescription drugs offer superior efficacy compared to over-the-counter alternatives for moderate-to-severe dermatological conditions. The expanding indications for prescription biologics drive sustained prescription volume growth across European nations. Reimbursement policies across Europe favor prescription-based treatments through comprehensive insurance coverage and national health service formularies. Dermatologists increasingly rely on prescription therapies as first-line interventions for chronic inflammatory skin diseases. The European Medicines Agency's approval of novel prescription therapies continues to expand the therapeutic landscape. Retail pharmacies maintain market leadership across Europe through extensive accessibility, established patient trust, and comprehensive service offerings for dermatological medications. Retail pharmacies serve as the primary touchpoint for patients seeking dermatological medications, offering convenient access across urban and suburban locations throughout Europe. These establishments provide professional pharmacist consultation, enhancing medication adherence and patient education on proper usage. Retail pharmacies maintain robust inventory management systems ensuring consistent availability of both prescription and OTC dermatological products. Established relationships with healthcare providers facilitate seamless prescription fulfillment and refill management processes across European healthcare systems. The expansion of retail pharmacy services includes fast delivery options and digital ordering platforms. Competitive pricing and national health service integration make retail pharmacies the preferred choice for cost-conscious consumers. Retail pharmacies offer comprehensive dermatological care solutions beyond dispensing, including skin health consultations and product recommendations.

to Download this information in a PDF

Dermatological Drugs Market Regional Insights

Germany dominates the European dermatological drugs market through its robust healthcare infrastructure, high disease prevalence, and sophisticated pharmaceutical innovation ecosystem. Germany represents the largest national market within Europe registering a CAGR of 6.88% between 2026 and 2031, benefiting from the world's most comprehensive healthcare system and substantial pharmaceutical research investments. Psoriasis affects approximately 1.83% of the Central European population. Germany reported approximately 48 thousand cases of alopecia areata in males and 97 thousand cases in females in 2023. The country's sophisticated regulatory environment, managed by the Federal Institute for Drugs and Medical Devices, facilitates efficient drug approval and market access. Significant investments in research and development drive the introduction of novel medications across therapeutic categories. Multiple pharmaceutical companies have received European Medicines Agency approvals for innovative products targeting diverse dermatological conditions. Favorable reimbursement policies through statutory health insurance support patient access to advanced therapies. The large number of individuals seeking affordable treatments fuels sustained market growth across Germany. Retail pharmacy expansions with novel offerings, including digital health integration, add lucrative growth opportunities throughout the country.

to Download this information in a PDF

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Companies Mentioned

Johnson & Johnson,
Pfizer Inc.
Novartis International AG
Sanofi S.A.
AbbVie Inc.
Bausch Health Companies Inc.
Eli Lilly and Company
Amgen Inc
Inmode Ltd
Haleon plc
Almirall, S.A.
LEO Pharma A/S

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Europe Dermatogical Drug Market Outlook
6.1. Market Size By Value
6.2. Market Share By Country
6.3. Market Size and Forecast, By Indication
6.4. Market Size and Forecast, By Drug Class / Molecule Type
6.5. Market Size and Forecast, By Route of Administration
6.6. Market Size and Forecast, By Drug Type
6.7. Market Size and Forecast, By Distribution channel
6.8. Germany Dermatogical Drug Market Outlook
6.8.1. Market Size by Value
6.8.2. Market Size and Forecast By Indication
6.8.3. Market Size and Forecast By Drug Class / Molecule Type
6.8.4. Market Size and Forecast By Route of Administration
6.8.5. Market Size and Forecast By Drug Type
6.8.6. Market Size and Forecast By Distribution channel
6.9. United Kingdom (UK) Dermatogical Drug Market Outlook
6.9.1. Market Size by Value
6.9.2. Market Size and Forecast By Indication
6.9.3. Market Size and Forecast By Drug Class / Molecule Type
6.9.4. Market Size and Forecast By Route of Administration
6.9.5. Market Size and Forecast By Drug Type
6.9.6. Market Size and Forecast By Distribution channel
6.10. France Dermatogical Drug Market Outlook
6.10.1. Market Size by Value
6.10.2. Market Size and Forecast By Indication
6.10.3. Market Size and Forecast By Drug Class / Molecule Type
6.10.4. Market Size and Forecast By Route of Administration
6.10.5. Market Size and Forecast By Drug Type
6.10.6. Market Size and Forecast By Distribution channel
6.11. Italy Dermatogical Drug Market Outlook
6.11.1. Market Size by Value
6.11.2. Market Size and Forecast By Indication
6.11.3. Market Size and Forecast By Drug Class / Molecule Type
6.11.4. Market Size and Forecast By Route of Administration
6.11.5. Market Size and Forecast By Drug Type
6.11.6. Market Size and Forecast By Distribution channel
6.12. Spain Dermatogical Drug Market Outlook
6.12.1. Market Size by Value
6.12.2. Market Size and Forecast By Indication
6.12.3. Market Size and Forecast By Drug Class / Molecule Type
6.12.4. Market Size and Forecast By Route of Administration
6.12.5. Market Size and Forecast By Drug Type
6.12.6. Market Size and Forecast By Distribution channel
6.13. Russia Dermatogical Drug Market Outlook
6.13.1. Market Size by Value
6.13.2. Market Size and Forecast By Indication
6.13.3. Market Size and Forecast By Drug Class / Molecule Type
6.13.4. Market Size and Forecast By Route of Administration
6.13.5. Market Size and Forecast By Drug Type
6.13.6. Market Size and Forecast By Distribution channel
7. Competitive Landscape
7.1. Competitive Dashboard
7.2. Business Strategies Adopted by Key Players
7.3. Porter's Five Forces
7.4. Company Profile
7.4.1. Galderma S.A.
7.4.1.1. Company Snapshot
7.4.1.2. Company Overview
7.4.1.3. Financial Highlights
7.4.1.4. Geographic Insights
7.4.1.5. Business Segment & Performance
7.4.1.6. Product Portfolio
7.4.1.7. Key Executives
7.4.1.8. Strategic Moves & Developments
7.4.2. LEO Pharma A/S
7.4.3. Almirall, S.A.
7.4.4. Bausch Health Companies Inc.
7.4.5. Haleon plc
7.4.6. AbbVie Inc.
7.4.7. Sanofi S.A.
7.4.8. Pfizer Inc.
7.4.9. Johnson & Johnson
7.4.10. Novartis AG
7.4.11. Eli Lilly and Company
7.4.12. Amgen Inc.
8. Strategic Recommendations
9. Annexure
9.1. FAQ`s
9.2. Notes
10. Disclaimer

Table 1: Influencing Factors for Dermatogical Drug Market, 2025
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Europe Dermatogical Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 6: Europe Dermatogical Drug Market Size and Forecast, By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 7: Europe Dermatogical Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 8: Europe Dermatogical Drug Market Size and Forecast, By Drug Type (2020 to 2031F) (In USD Billion)
Table 9: Europe Dermatogical Drug Market Size and Forecast, By Distribution channel (2020 to 2031F) (In USD Billion)
Table 10: Germany Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 11: Germany Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 12: Germany Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 13: Germany Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 14: Germany Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 15: United Kingdom (UK) Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 16: United Kingdom (UK) Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 17: United Kingdom (UK) Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 18: United Kingdom (UK) Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 19: United Kingdom (UK) Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 20: France Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 21: France Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 22: France Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 23: France Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 24: France Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 25: Italy Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 26: Italy Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 27: Italy Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 28: Italy Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 29: Italy Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 30: Spain Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 31: Spain Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 32: Spain Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 33: Spain Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 34: Spain Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 35: Russia Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 36: Russia Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 37: Russia Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 38: Russia Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 39: Russia Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 40: Competitive Dashboard of top 5 players, 2025

Figure 1: Europe Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 2: Europe Dermatogical Drug Market Share By Country (2025)
Figure 3: Germany Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: United Kingdom (UK) Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: France Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Italy Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: Spain Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Russia Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Porter's Five Forces of Global Dermatogical Drug Market

Dermatological Drugs Market Research FAQs

Atopic dermatitis affects approximately 4.4% of European adults and up to 18.6% of children and adolescents, with 20% of all cases classified as moderate-to-severe.

Almirall leads with its European dermatology business achieving 24.2% year-on-year growth, while Galderma has strengthened its position following European Commission approval of Nemluvio.

The CHMP issued a positive opinion for ruxolitinib cream for moderate atopic dermatitis in June 2026 and recommended nemolizumab approval for atopic dermatitis and prurigo nodularis in February 2025.

Health technology assessment bodies across individual European nations create a complex reimbursement landscape, with each country maintaining independent processes for market access and pricing.

Moderate-to-severe atopic dermatitis results in annual societal costs of approximately €30 billion across Europe, including €15.2 billion from lost work productivity and €10.1 billion in direct medical costs.

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted